LONDON (Reuters) - Europe's medicines regulator said on Monday it was ready to offer Ebola treatments and vaccines the benefits of "orphan" drug status -- including extended market exclusivity -- in a bid to encourage their development.
The European Medicines Agency (EMA) said orphan status could be granted for experimental drugs intended for life-threatening conditions affecting no more than five in 10,000 people in the European Union, as is the case for Ebola.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!